Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GC-101 by Shanghai Juncell Therapeutics for Cervical Cancer: Likelihood of Approval
GC-101 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData,...
Data Insights
GC-101 by Shanghai Juncell Therapeutics for Metastatic Melanoma: Likelihood of Approval
GC-101 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData,...